Table 3.
Summary of significant sex x diagnosis interactions of serum molecules measured by multiplex immunoassay
| |
Interaction |
Males |
Females |
|||
|---|---|---|---|---|---|---|
| Protein | P -value | q-value | Ratio | P -value | Ratio | P -value |
| Bone morphogenic protein-6 (BMP6) |
0.023 |
0.193 |
3.04 |
0.001 |
0.85 |
0.703 |
|
Tumour necrosis factor-alpha (TNF) |
0.017 |
0.191 |
1.45 |
0.003 |
1.02 |
0.192 |
|
Tissue factor (TF) |
0.012 |
0.154 |
1.39 |
0.001 |
0.73 |
0.151 |
|
Connective tissue growth factor (CTGF) |
0.001 |
0.037 |
1.29 |
0.001 |
0.83 |
0.091 |
| Interleukin-16 (IL-16) |
0.025 |
0.196 |
1.17 |
0.008 |
0.88 |
0.134 |
|
Interleukin-12p70 (IL-12p70) |
0.005 |
0.070 |
1.16 |
0.008 |
0.91 |
0.074 |
|
Intracellular adhesion molecule-1 (ICAM1) |
0.027 |
0.196 |
1.15 |
0.010 |
1.00 |
0.343 |
|
Chromogranin A (CHGA) |
<0.001 |
0.008 |
1.70 |
0.001 |
0.77 |
0.019 |
|
Tenascin C (TENA) |
0.002 |
0.037 |
1.28 |
0.049 |
0.66 |
0.007 |
|
Sex hormone binding globulin (SHBG) |
0.026 |
0.191 |
1.20 |
0.036 |
0.76 |
0.065 |
| Prostatic acid phosphatase (PAP) |
0.004 |
0.058 |
1.19 |
0.040 |
0.82 |
0.028 |
|
Erythropoietin (EPO) |
0.044 |
0.282 |
0.49 |
0.021 |
1.36 |
0.060 |
|
Interleukin-3 (IL-3) |
<0.001 |
0.022 |
0.28 |
0.006 |
1.87 |
0.039 |
| Adiponectin (ADIPO) |
0.037 |
0.251 |
1.19 |
0.453 |
0.77 |
0.037 |
| Immunoglobulin A (IgA) |
0.022 |
0.192 |
1.05 |
0.852 |
0.73 |
0.006 |
| Apolipoprotein A1 (APOA1) | 0.002 | 0.037 | 1.05 | 0.857 | 0.63 | 0.001 |
Indicated are the P-values and FDR (false discovery rate) of the sex-diagnosis interactions and the separate ratio (AS/control; calculated using geometric means) changes with P-values in males in females. Values in bold font indicate significant sex differences in individuals with AS and typical individuals. Analytes in italic style font were identified in our previous study of AS individuals, which did not account for potential drug effects [6]. In the overlapping region, changes in molecular levels are in opposite directions in males and females.